Corcept Therapeutics Incorporated (NASDAQ:CORT) reported Q2 2017 earnings this Afternoon, coming in at $0.10 per share, beating Wall Street’s estimates of $0.07 per Share. Revenue for the quarter came in at $35.56 million beating analyst estimates of $31.37 million
Analyst Coverage For Corcept Therapeutics Incorporated (NASDAQ:CORT)
These are 1 Sell Rating, 3 Buy Ratings .
The current consensus rating for Corcept Therapeutics Incorporated (NASDAQ:CORT) is Buy (Score: 2.50) with a consensus target price of $14.25 , a potential (15.85% upside)Recent Insider Trading for Corcept Therapeutics Incorporated (NASDAQ:CORT)
- On 7/19/2017 David L Mahoney, Director, sold 23,006 with an average share price of $12.50 per share and the total transaction amounting to $287,575.00.
- On 7/18/2017 David L Mahoney, Director, sold 6,091 with an average share price of $12.50 per share and the total transaction amounting to $76,137.50.
- On 7/13/2017 David L Mahoney, Director, sold 6,994 with an average share price of $12.50 per share and the total transaction amounting to $87,425.00.
- On 7/12/2017 David L Mahoney, Director, sold 6,510 with an average share price of $12.50 per share and the total transaction amounting to $81,375.00.
- On 5/4/2017 Gary Charles Robb, CFO, bought 5,600 with an average share price of $9.75 per share and the total transaction amounting to $54,600.00.
- On 3/16/2017 Patrick G. Enright, Director, sold 269,955 with an average share price of $9.94 per share and the total transaction amounting to $2,683,352.70.
Recent Trading for Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares of Corcept Therapeutics Incorporated closed the previous trading session at 12.30 down -0.17 -1.36% with 728,448 shares trading hands.